Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco ...

DexCom, Inc. DXCM reported first-quarter 2026 adjusted earnings per share (EPS) of 56 cents, which beat the Zacks Consensus ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either DexCom (DXCM) or Masimo (MASI). But which of these two stocks presents investors with the better value ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are ...

DexCom (DXCM) delivered earnings and revenue surprises of +19.66% and +1.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...

Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s. The company ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...